Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 10/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | MYC | P01106 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372633 | 1.00 | CFTR (0.45) | CFTRNOTUMMYCALDH1A1KDM4E | |
| SCHEMBL13518970 | 0.95 | CFTR (0.42) | CFTRNOTUMMYCALDH1A1KDM4E | |
| SCHEMBL2383885 | 0.86 | MYC (0.43) | CFTRNOTUMMYCALDH1A1KDM4E | |
| SCHEMBL2372372 | 0.86 | MYC (0.43) | CFTRNOTUMMYCALDH1A1KDM4E | |
| SCHEMBL29699241 | 0.86 | CFTR (0.45) | CFTRMYCHSD17B10 | |
| SCHEMBL2372056 | 0.86 | CFTR (0.45) | CFTRMYCHSD17B10 | |
| SCHEMBL2381481 | 0.85 | CFTR (0.42) | CFTRNOTUMMYCALDH1A1KDM4E | |
| SCHEMBL12295762 | 0.85 | CFTR (0.40) | CFTRNOTUMMYCALDH1A1KDM4E | |
| SCHEMBL2372480 | 0.81 | CFTR (0.40) | CFTRNOTUMMYCALDH1A1KDM4E | |
| SCHEMBL2372871 | 0.81 | CFTR (0.45) | CFTRNOTUMMYCALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3980121-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | Novartis AG (CH) | 2022-04-13 | — | — | EP | disclosed |